Acute myocardial infarction associated with initial alemtuzumab infusion cycle in relapsing-remitting multiple sclerosis.

Publication Title

Mult Scler Relat Disord

Authors

Meghan C Romba, Providence Multiple Sclerosis Center, Providence Brain and Spine Institute, Portland, OR 97225, USAFollow
Scott D Newsome
Justin C McArthur

Document Type

Article

Publication Date

6-18-2019

Abstract

Alemtuzumab is an anti-CD52 monoclonal antibody used for the treatment of lymphoproliferative disorders and relapsing-remitting multiple sclerosis. We report a 30-year-old woman with relapsing-remitting multiple sclerosis who developed a type 2 non-ST elevated myocardial infarction (NSTEMI) during her first alemtuzumab infusion cycle. While acute coronary syndrome has been described with alemtuzumab in the treatment of lymphoma, alemtuzumab-associated cardiac ischemia in multiple sclerosis is uncommon and can occur in patients without cardiovascular risk factors.

Clinical Institute

Neurosciences (Brain & Spine)

Specialty/Research Institute

Neurosciences